32966798|t|Limiting RyR2 Open Time Prevents Alzheimer's Disease-Related Neuronal Hyperactivity and Memory Loss but Not beta-Amyloid Accumulation.
32966798|a|Neuronal hyperactivity is an early primary dysfunction in Alzheimer's disease (AD) in humans and animal models, but effective neuronal hyperactivity-directed anti-AD therapeutic agents are lacking. Here we define a previously unknown mode of ryanodine receptor 2 (RyR2) control of neuronal hyperactivity and AD progression. We show that a single RyR2 point mutation, E4872Q, which reduces RyR2 open time, prevents hyperexcitability, hyperactivity, memory impairment, neuronal cell death, and dendritic spine loss in a severe early-onset AD mouse model (5xFAD). The RyR2-E4872Q mutation upregulates hippocampal CA1-pyramidal cell A-type K+ current, a well-known neuronal excitability control that is downregulated in AD. Pharmacologically limiting RyR2 open time with the R-carvedilol enantiomer (but not racemic carvedilol) prevents and rescues neuronal hyperactivity, memory impairment, and neuron loss even in late stages of AD. These AD-related deficits are prevented even with continued beta-amyloid accumulation. Thus, limiting RyR2 open time may be a hyperactivity-directed, non-beta-amyloid-targeted anti-AD strategy.
32966798	9	13	RyR2	Gene	20191
32966798	33	52	Alzheimer's Disease	Disease	MESH:D000544
32966798	61	83	Neuronal Hyperactivity	Disease	MESH:D001289
32966798	88	99	Memory Loss	Disease	MESH:D008569
32966798	135	157	Neuronal hyperactivity	Disease	MESH:D001289
32966798	193	212	Alzheimer's disease	Disease	MESH:D000544
32966798	214	216	AD	Disease	MESH:D000544
32966798	221	227	humans	Species	9606
32966798	261	283	neuronal hyperactivity	Disease	MESH:D001289
32966798	298	300	AD	Disease	MESH:D000544
32966798	377	397	ryanodine receptor 2	Gene	20191
32966798	399	403	RyR2	Gene	20191
32966798	416	438	neuronal hyperactivity	Disease	MESH:D001289
32966798	443	445	AD	Disease	MESH:D000544
32966798	481	485	RyR2	Gene	20191
32966798	502	508	E4872Q	ProteinMutation	tmVar:p|SUB|E|4872|Q;HGVS:p.E4872Q;VariantGroup:0;OriginalGene:20191;CorrespondingGene:6262;CorrespondingSpecies:10090
32966798	524	528	RyR2	Gene	20191
32966798	568	581	hyperactivity	Disease	MESH:D006948
32966798	583	600	memory impairment	Disease	MESH:D008569
32966798	672	674	AD	Disease	MESH:D000544
32966798	675	680	mouse	Species	10090
32966798	688	693	5xFAD	Disease	
32966798	700	704	RyR2	Gene	20191
32966798	705	711	E4872Q	ProteinMutation	tmVar:p|SUB|E|4872|Q;HGVS:p.E4872Q;VariantGroup:0;OriginalGene:20191;CorrespondingGene:6262;CorrespondingSpecies:10090
32966798	851	853	AD	Disease	MESH:D000544
32966798	882	886	RyR2	Gene	20191
32966798	906	918	R-carvedilol	Chemical	MESH:D000077261
32966798	947	957	carvedilol	Chemical	MESH:D000077261
32966798	980	1002	neuronal hyperactivity	Disease	MESH:D001289
32966798	1004	1021	memory impairment	Disease	MESH:D008569
32966798	1027	1038	neuron loss	Disease	MESH:D009410
32966798	1062	1064	AD	Disease	MESH:D000544
32966798	1072	1074	AD	Disease	MESH:D000544
32966798	1168	1172	RyR2	Gene	20191
32966798	1192	1205	hyperactivity	Disease	MESH:D006948
32966798	1247	1249	AD	Disease	MESH:D000544
32966798	Association	MESH:D000544	HGVS:p.E4872Q;CorrespondingGene:6262
32966798	Negative_Correlation	MESH:D000077261	MESH:D008569
32966798	Negative_Correlation	MESH:D008569	HGVS:p.E4872Q;CorrespondingGene:6262
32966798	Association	MESH:D009410	20191
32966798	Association	MESH:D000544	20191
32966798	Negative_Correlation	MESH:D006948	HGVS:p.E4872Q;CorrespondingGene:6262
32966798	Negative_Correlation	MESH:D000077261	MESH:D009410
32966798	Association	MESH:D000077261	20191
32966798	Association	MESH:D001289	20191
32966798	Association	MESH:D008569	20191
32966798	Association	MESH:D006948	20191
32966798	Negative_Correlation	MESH:D000077261	MESH:D001289
32966798	Association	MESH:D000544	6262
32966798	Association	MESH:D008569	6262
32966798	Association	MESH:D006948	6262

